Neuropathic Pain 

NEUROPATHIC PAIN

BRIEF This guide translates Neuropatic pain: Fundamental neurophysiology and pharmacology into structured bedside diagnostic and therapeutic pathways.

DEFINITION AND ETIOLOGY

• Neuropathic pain: Defined by the International Association for the Study of Pain (IASP) as pain caused by a lesion or disease of the somatosensory nervous system . 
• It is critical to recognize that neuropathic pain is not a single disease entity, but rather a clinical symptom of diverse underlying pathologies. 
• It arises from damage or disease affecting either the peripheral or central nervous system. In the clinical setting, neuropathic pain frequently coexists with traditional nociceptive pain, presenting as a highly complex pain 
• The table below outlines the anatomical localizations and primary causes of peripheral and central neuropathic pain.

Anatomical Level	Etiological Category	Clinical Examples & Pathological Process
Peripheral Nervous System	Metabolic, Infectious, Traumatic, Toxic, or Idiopathic	• Painful diabetic neuropathy: Length-dependent, symmetric distal axonal loss. • Post-herpetic neuralgia: Persistent dermatomal pain following herpes zoster reactivation. • Radiculopathy: Nerve root compression secondary to herniated discs or spinal stenosis. • Post-surgical nerve injury: Transection or entrapment of peripheral nerves during surgery. • Chemotherapy-induced neuropathy: Toxic axonal damage affecting small- and large-fibre pathways. • Trigeminal neuralgia: Focal demyelination at the nerve root entry zone due to vascular compression.
Central Nervous System	Trauma, Vascular, or Demyelinating Disease	• Spinal cord injury: Segmental pain at the level of lesion, or diffuse pain below the lesion. • Central post-stroke pain: Unilateral pain and sensory impairment secondary to thalamic or cortical vascular injury. • Multiple sclerosis: Central pain resulting from demyelinating plaques within somatosensory pathways.

The Table below contrasts the distinct pathophysiological, qualitative, and therapeutic differences between nociceptive and neuropathic pain states.

Clinical Feature	Nociceptive Pain	Neuropathic Pain
Pathophysiological Basis	Stimulation of intact nociceptors by noxious thermal, mechanical, or chemical stimuli in response to actual or threatened tissue injury.	Pathological changes, damage, or disease affecting the somatosensory pathways in either the peripheral or central nervous system.
Pain Quality	Aching, throbbing, dull, sharp, or localized pressure; usually matches the stimulus intensity and localizes well.	Burning, shooting, stabbing, electric-shock-like, tingling, lancinating, or crushing; often coexists with abnormal sensory sensations.
Sensory Examination	Normal somatosensory function. Sensory testing does not reveal deficits; localized tenderness or inflammatory swelling may be present.	Objective sensory deficits (numbness, hypoesthesia to touch/temp) coexisting with paradoxical sensory gain (allodynia, hyperalgesia).
Response to Opioids	Highly responsive to standard opioid titrations, paracetamol, non-steroidal anti-inflammatory drugs (NSAIDs), and local blocks.	Partially responsive or highly resistant to standard opioids; requires specific neuromodulators (e.g., gabapentinoids, TCAs).
Examples	Postoperative surgical wound pain, acute inflammatory arthritis, chest tube irritation, acute burns, skeletal fractures.	Phantom limb pain, trigeminal neuralgia, post-herpetic neuralgia, painful diabetic peripheral neuropathy.

PHYSIOLOGICAL MECHANISMS AND NEUROBIOLOGY

The neurobiology of neuropathic pain involves profound neuroplasticity across both peripheral and central somatosensory systems. 

Peripheral Hyperexcitability

Following peripheral nerve injury, damaged axons and primary afferent neurons in the dorsal root ganglion (DRG) undergo major functional remodeling.

 Key mechanisms:

• Altered expression and retrograde redistribution of voltage-gated sodium channels, particularly the Nav1.7, Nav1.8, and Nav1.9 subtypes.
•  This dramatic up-regulation lowers the activation threshold for action potential generation, facilitating ectopic pacemaking (spontaneous discharge) and mechanical hypersensitivity .
• Accumulation of local inflammatory mediators (the ‘inflammatory soup’) released by injured tissue, resident macrophages, and degranulated mast cells. This soup contains prostaglandins, bradykinin, tumour necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1beta), and nerve growth factor (NGF) .
• Activation of second-messenger cascades (Protein Kinase A and C) within the nociceptor membrane. This phosphorylates channel proteins, decreasing the activation threshold of transient receptor potential channels (specifically TRPV1) and voltage-gated sodium channels, a phenomenon termed peripheral sensitisation .

Central Sensitisation

• Persistent, high-frequency ectopic discharge from the hyperactive periphery drives profound, long-term synaptic plasticity within the spinal dorsal horn (laminae I, II, and V).
• This transition from acute nociceptive signalling to established central hypersensitivity occurs via a structured biochemical cascade:

1. Presynaptic Neurotransmitter Release: Sustained presynaptic depolarisation triggers the excessive release of primary excitatory neurotransmitters—primarily glutamate—alongside co-transmitters such as Substance P into the synaptic cleft .

2. AMPA Receptor Activation and Postsynaptic Depolarisation: Glutamate binds to postsynaptic AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors, generating rapid sodium (Na+) influx and robust depolarisation of the postsynaptic membrane .

3. Expulsion of the NMDA Magnesium Block: Under normal resting conditions, the channel pore of the NMDA (N-methyl-D-aspartate) receptor is physically blocked by a magnesium (Mg2+) ion. The sustained membrane depolarisation mediated by AMPA receptor activation expels this Mg2+ plug from the channel pore .

4. Intracellular Calcium Influx: Unblocked NMDA receptors permit a massive influx of extracellular calcium (Ca2+) into the postsynaptic neuron .

5. Activation of Kinase Cascades: The surge in intracellular Ca2+ acts as a second messenger, activating a suite of calcium-dependent protein kinases, including Protein Kinase C (PKC), Calcium/Calmodulin-dependent Protein Kinase II (CaMKII), and Mitogen-Activated Protein Kinase / Extracellular Signal-Regulated Kinase (MAPK/ERK) .

6. Synaptic Potentiation and Hypersensitivity: These activated kinases phosphorylate postsynaptic AMPA and NMDA receptors, increasing their open-probability and facilitating the trafficking of additional receptors to the postsynaptic density. These kinases also drive gene transcription, leading to a persistent, long-term enhancement of synaptic transmission, analogous to long-term potentiation (LTP) .

Loss of Interneuronal Control and Spinal Glial Activation

In addition to synaptic excitation, neuropathic pain is sustained by a loss of endogenous spinal inhibition and active neuroinflammatory signaling:

• Under physiological conditions, spinal interneurons release GABA and glycine to filter incoming nociceptive signals. Following nerve injury, there is marked interneuronal apoptosis and a reduction in GABA/glycine synthesis, causing disinhibition (loss of filter) and allowing light touch to be perceived as severe pain (allodynia) .
• Descending inhibitory pathways originating in the periaqueductal grey (PAG) and rostral ventromedial medulla (RVM)—which release noradrenaline and serotonin—are severely blunted .
• Spinal glial cells (microglia and astrocytes) are activated by neuronal chemokines (such as CCL2, fractalkine/CX3CL1). Activated microglia release brain-derived neurotrophic factor (BDNF) which binds to TrkB receptors on postsynaptic dorsal horn neurons, shifting the chloride gradient and rendering GABAergic inputs depolarising (excitatory) rather than hyperpolarising (inhibitory) .

CLINICAL PRESENTATION AND DIAGNOSTIC FRAMEWORKS

Symptomatology and the Bedside testing

Symptom Class	Clinical Term	Physiological Definition	Bedside Testing Technique
Positive Signs (Sensory Gain)	Paraesthesia	An abnormal, spontaneous, non-painful, and usually transient sensation (e.g., tingling, ‘pins and needles’).	Identified through patient self-report during history taking.
Positive Signs (Sensory Gain)	Dysaesthesia	An abnormal, spontaneous or evoked, unpleasant or painful sensation (e.g., crawling, burning, or acid-like pain).	Identified via patient description or evoked during routine light touch testing.
Positive Signs (Sensory Gain)	Hyperalgesia	An increased, exaggerated pain response to a stimulus that is normally painful (nociceptor pathway amplification).	Evoked by light prick with a standard neurological safety pin (assessment of mechanical nociception).
Positive Signs (Sensory Gain)	Allodynia	Pain provoked by a stimulus that does not normally provoke pain (e.g., light touch, sheets, warm water).	• Dynamic mechanical: Lightly stroking skin with a cotton wisp. • Thermal: Applying warm/cool metal rollers or water-filled tubes.
Negative Signs (Sensory Loss)	Hypoaesthesia	A pathological reduction in sensitivity to tactile, thermal, or painful stimulation.	Evoked by brushing skin with cotton or using hot/cold metal objects, comparing with a normal control area.
Negative Signs (Sensory Loss)	Hypoalgesia	A pathological reduction in pain perception in response to a normally painful stimulus.	Evoked by applying standard pinprick testing, demonstrating blunted or absent sharp sensation.
Negative Signs (Sensory Loss)	Sensory Deficits	Loss of vibration, joint position, or touch-pressure perception (indicates large-fibre demyelination/axonal loss).	• Vibration: 128 Hz tuning fork over bony prominences. • Proprioception: Bedside joint position testing.

Neuroanatomical Mapping

A foundational rule of neuropathic pain diagnosis is that the territory of pain must match a neuroanatomically plausible distribution. Sensory loss and pain typically overlap in the same distribution:

• Stocking-Glove Distribution: Symmetric, length-dependent distal axonal loss, typically starting in the lower extremities (‘dying-back’ neuropathy). Common in diabetic, uremic, or chemotherapy-induced peripheral neuropathy.

• Dermatomal Distribution: Pain and sensory abnormalities restricted strictly to a spinal dermatomal region, classic for acute shingles, post-herpetic neuralgia, or lumbosacral/cervical radiculopathy.

• Peripheral Nerve Territory: Pain isolated to the specific territory of a single peripheral nerve, such as the lateral femoral cutaneous nerve in meralgia paresthetica, or post-surgical nerve entrapment.

The IASP Diagnostic Certainty Matrix

• The IASP categorization of Possible, Probable, and Definite neuropathic pain is a standard examination topic. 
• It provides a structured step-by-step approach to diagnostic validation:

Certainty Grade	Required Clinical Criteria	Bedside & Investigative Validation
Possible Neuropathic Pain	1. History suggests a relevant neurological lesion or disease. 2. Pain is distributed within a plausible neuroanatomical territory.	Bedside mapping of pain territory and correlation with clinical history (e.g., patient with dermatomal pain following shingles). No objective examination signs required.
Probable Neuropathic Pain	Meets criteria for Possible pain, PLUS: 3. Objective sensory signs demonstrate sensory loss or gain confined within the neuroanatomical distribution.	Bedside physical exam demonstrates objective sensory loss (hypoesthesia/hypoalgesia) or sensory gain (allodynia/hyperalgesia) localized strictly within the pain distribution.
Definite Neuropathic Pain	Meets criteria for Probable pain, PLUS: 4. Objective diagnostic confirmation of the underlying somatosensory lesion or disease.	Positive results on definitive diagnostic investigations, such as EMG/NCS, skin biopsy showing reduced intraepidermal nerve-fibre density, or MRI demonstrating spinal cord pathology.

• Validated screening instruments (e.g., DN4, LANSS, painDETECT) support neuropathic pain identification in non-specialist settings. A score of >= 4 out of 10 on the DN4 (which combines 7 interview questions and 3 physical tests) provides high sensitivity and specificity. 
• However, these tools are adjuncts and do not replace a comprehensive neuroanatomical examination.

INVESTIGATIONS 

Diagnostic Investigations

Investigations must target the suspected underlying pathology and should be systematically prioritized based on fiber type and anatomical location:

• Metabolic & Systemic Screening: Glucose, HbA1c, Vitamin B12, thyroid-stimulating hormone (TSH), renal panels, liver function tests, and serum protein electrophoresis (SPEP) are key to diagnosing metabolic, endocrine, nutritional, toxic, or paraproteinaemic neuropathies.

• Nerve Conduction Studies & Electromyography (NCS/EMG): Highly sensitive for assessing large, myelinated nerve fibres. Essential for diagnosing radiculopathy, demyelinating polyneuropathies, and focal nerve entrapments. Crucial Exam Point: Normal nerve conduction studies do NOT exclude neuropathic pain, as they cannot assess small-diameter A-delta and C fibres.

• Skin Biopsy for Intraepidermal Nerve-Fibre Density (IENFD): The absolute gold standard for confirming small-fibre neuropathies. A 3 mm punch biopsy of the distal calf is analyzed using immunohistochemistry to visualize and count epidermal nerve endings.

• Quantitative Sensory Testing (QST): A standardized psychophysical testing protocol assessing thermal and mechanical thresholds to map both small- and large-fibre somatosensory pathways.

• Magnetic Resonance Imaging (MRI): Indicated when central neurological disease (e.g., stroke, multiple sclerosis plaques) or structural compression (e.g., herniated discs, nerve root entrapment, spinal cord compression) is suspected.

Pharmacological Drugs : First-Line Modulators

Pharmacological management requires matching drug mechanisms to the underlying pathophysiology while navigating side effect profiles, organ clearances, and drug interactions.

Drug Class & Agent	Primary Mechanism of Action	Core Clinical Indications	Key Adverse Effects & Risks	Critical Exam & Clinical Pearls
Tricyclic Antidepressants (TCAs) *Amitriptyline*	Inhibits serotonin and noradrenaline reuptake (enhancing descending inhibition); blocks -dependent sodium channels and postsynaptic muscarinic (M1), histaminergic (H1), and alpha-1 receptors .	Broad-spectrum chronic neuropathic pain; post-herpetic neuralgia; fibromyalgia; tension headache prophylaxis .	Profound somnolence,dry mouth, urinary retention, severe constipation, blurred vision, orthostatic hypotension, cardiac conduction delay (QTc prolongation, heart block) .	• Avoid in elderly patients (extreme falls risk due to orthostatic hypotension and sedation). • Baseline ECG is mandatory to check for QTc prolongation. • Administer at night to utilize sedative properties .
Serotonin-Noradrenaline Reuptake Inhibitors (SNRIs) *Duloxetine*	Potent, selective inhibitor of serotonin and noradrenaline reuptake, enhancing endogenous descending monoaminergic inhibitory modulation	Painful diabetic peripheral neuropathy; neuropathic pain with coexisting depression or anxiety	Nausea, dry mouth, headache, somnolence, hyperhidrosis, mild elevation of blood pressure	•Contraindicated in severe renal impairment (GFR < 30 mL/min). • Excellent alternative to TCAs in elderly or cardiac patients due to minimal anticholinergic and cardiac profiles
Gabapentinoids *Gabapentin, Pregabalin*	Binds selectively and with high affinity to the alpha-2-delta subunit of voltage-gated calcium channels This reduces presynaptic calcium influx and the exocytosis of excitatory neurotransmitters (glutamate, Substance P).	Diabetic peripheral neuropathy, post-herpetic neuralgia, central neuropathic pain (e.g., spinal cord injury)	Somnolence, dizziness, ataxia, cognitive slowing, peripheral oedema, weight gain	• Exclusively renally cleared; strict dose reductions are mandatory in renal impairment. • High risk of synergistic respiratory depression when combined with opioids or other central depressants.
Topical Lidocaine *5% Patch / Gel*	Local, use-dependent blockade of voltage-gated sodium channels, stabilizing hyperactive primary nociceptor membranes and suppressing ectopic discharge	Focal, localized peripheral neuropathic pain; post-herpetic neuralgia; localized surgical scars	Localized erythema, skin irritation, mild pruritus; virtually free of systemic side effects	• Highly suited for elderly or medically fragile patients due to negligible systemic absorption. • Apply for a maximum of 12 hours per day (12-hours-on, 12-hours-off)
Topical Capsaicin *8% Patch  Cream*	Activates TRPV1 channels, leading to intracellular calcium overload in primary nociceptor terminals, causing temporary functional desensitisation and retraction of sensory fibres [3].	Focal peripheral neuropathic pain (post-herpetic neuralgia, post-surgical scars) .	Intense local burning, erythema, localized swelling, transient pain escalation during application .	• High-concentration 8% patch must be applied in a clinical setting under local anaesthetic pre-treatment. • Single application can provide pain relief for up to 3 months.
Anticonvulsants *Carbamazepine*	Blocks use-dependent voltage-gated sodium channels, preventing high-frequency repetitive action potentials in hyperexcitable primary afferents .	First-line pharmacological treatment for Trigeminal Neuralgia .	Dizziness, diplopia, ataxia, hyponatremia (SIADH), leukopenia, aplastic anaemia, severe cutaneous adverse reactions .	• Strong inducer of CYP3A4, causing numerous drug-drug interactions. • Routine monitoring of full blood count, sodium levels, and serum drug levels is required. • Screen for HLA-B*1502 allele in Asian patients before initiation .

• Opioids are generally not preferred as routine long-term therapy for chronic neuropathic pain due to significant risks of tolerance, dependence, sedation, severe constipation, respiratory depression, and opioid-induced hyperalgesia .
•  In selected clinical cases, tramadol may serve as a short-term rescue therapy, but long-term opioid escalation should prompt a reassessment of the diagnosis and treatment plan.

INTENSIVE CARE AND ANAESTHESIA RELEVANCE

. It plays a major role in the development of persistent post-surgical pain (PPSP) and presents unique assessment and safety challenges in critically ill patients.

Persistent Post-Surgical Pain (PPSP)

Preventing the transition from acute post-operative nociceptive pain to chronic neuropathic pain is a core clinical goal. Surgical procedures involving nerve compression, stretch, or transection carry a substantial risk of PPSP with neuropathic characteristics:

• Thoracotomy: Occurs in up to 50% of patients. Primary cause is intercostal nerve compression, stretch, or entrapment by rib retractors or sutures during chest closure .

• Mastectomy: Occurs in up to 30% of patients, primarily due to surgical damage to the intercostobrachial nerve .

• Limb Amputation: Phantom limb pain and stump pain occur in 50% to 80% of amputees, driven by peripheral neuroma formation and subsequent central somatosensory remodeling.

• Hernia Surgery: Occurs in up to 10% of patients, caused by ilioinguinal, iliohypogastric, or genitofemoral nerve entrapment by surgical sutures or mesh .

Clinical preventative strategies rely on aggressive, multi-modal perioperative analgesia—specifically utilizing regional anaesthesia (e.g., epidural or paravertebral blocks), gabapentinoids, and NMDA antagonists (low-dose ketamine) to block nociceptive bombardment and prevent central spinal cord remodeling.

The ICU Assessment Challenge

Clinicians must maintain a high index of suspicion and suspect neuropathic pain in patients who have experienced:

• Direct trauma, surgical nerve injuries, or prolonged surgical positioning errors (e.g., ulnar or peroneal nerve compression) .
• Prolonged prone ventilation for severe ARDS, which carries a high risk of brachial plexus stretch and compression injury.
• Pre-existing or acute spinal cord injury, traumatic brain injury, or stroke .
• Acute infectious neurological complications, such as acute herpes zoster (shingles) in immunocompromised patients .

Critical Care Pharmacology and Safety Hazards

Using neuromodulatory agents in the ICU requires extreme caution. Two critical hazards must be managed:

1. Sedation and Synergistic Respiratory Depression: 

• Gabapentinoids (gabapentin and pregabalin) act synergistically with opioids, benzodiazepines, propofol, and dexmedetomidine. 
• This combination significantly increases the risk of deep sedation, loss of airway reflexes, and hypercapnic respiratory depression .

2. Renal Clearance and Accumulation:

• Gabapentinoids are cleared exclusively by the kidneys and are not protein-bound. In patients with Acute Kidney Injury (AKI), severe chronic kidney disease, or on Continuous Renal Replacement Therapy (CRRT), these drugs accumulate rapidly.
•  Toxicity manifests as severe, prolonged somnolence, myoclonus, diaphragmatic weakness (delaying weaning from mechanical ventilation), and seizures. Proactive and aggressive dose reduction based on daily creatinine clearance is mandatory.

ICU Differential Diagnosis of Mixed Pain States

However, clinicians must distinguish between four coexisting, overlapping pain states: nociceptive pain, neuropathic pain, opioid tolerance, and opioid-induced hyperalgesia (OIH). 

Clinical Feature	Nociceptive Pain	Neuropathic Pain	Opioid Tolerance	Opioid-Induced Hyperalgesia (OIH)
Pathophysiological Basis	Stimulation of intact peripheral nociceptors by noxious inflammatory or mechanical stimuli in response to tissue injury .	Pathological lesion, damage, or disease affecting somatosensory pathways in either the peripheral or central nervous system .	Pharmacological neuroadaptation where escalating opioid doses are required to maintain a given level of analgesia over time .	Paradoxical state where exposure to escalating opioid doses increases pain sensitivity, worsening overall clinical pain .
Pain Distribution	Localized strictly to the site of tissue injury or inflammation (e.g., surgical incision, chest tube site) .	Plausible neuroanatomical distribution (dermatomal, stocking-glove, or peripheral nerve territory) .	Remains localized; matches the distribution of the original underlying pain pathology.	Diffuse, poorly localized pain that extends far beyond the original tissue injury (hyperpathia/allodynia at distant sites) .
Pain Descriptors	Throbbing, aching, sharp, dull, sore.	Burning, shooting, stabbing, electric-shock-like, tingling, lancinating.	Aching, throbbing; matches the characteristics of the original underlying pain.	Diffuse burning, allodynia to light touch, or intense aching in unrelated areas .
Primary Mechanism	Chemical, thermal, or mechanical transduction in peripheral nociceptors.	Sodium channel remodeling, peripheral ectopic firing, spinal central sensitisation, disinhibition .	Down-regulation and desensitisation of mu-opioid receptors; decoupling from G-proteins.	Up-regulation of spinal NMDA receptors, microglial activation, release of pronociceptive dynorphins and CGRP.
Response to Opioid Escalation	Excellent; standard opioid titration resolves the pain .	Moderate to poor; escalation yields limited analgesia with increased side effects .	Pain is temporarily relieved, but requires progressively higher doses .	Pain paradoxically worsens with opioid escalation; improves with opioid weaning .
Standard Management	Systemic opioids, paracetamol, NSAIDs, regional nerve blocks.	Amitriptyline, Gabapentinoids, SNRIs, topical lidocaine, low-dose ketamine .	Gradual opioid titration, addition of non-opioid multimodal analgesics.	Proactive opioid weaning; opioid rotation (e.g., to buprenorphine); NMDA antagonists (ketamine, magnesium).

THE PRACTICAL APPROACH

• 1. Identify the Pain Phenotype: Perform a thorough bedside exam. Identify typical descriptors (burning, shooting) and characterize sensory abnormalities: distinguish positive signs (allodynia, hyperalgesia) from negative signs (sensory loss) .
• 2. Map the Neuroanatomical Territory: Ensure the pain distribution corresponds strictly to a neuroanatomically plausible pattern (e.g., stocking-glove, dermatomal, or single peripheral nerve distribution) to achieve ‘Probable’ diagnostic certainty .
• 3. Investigate and Address the Underlying Cause: Conduct structured diagnostics and imaging/electrophysiology to identify and treat the primary underlying cause (e.g., decompression of nerve root, glycemic control) .
• 4. Initiate Mechanism-Based Pharmacotherapy:. Avoid TCAs in patients with severe cardiac disease or fall risk. Avoid duloxetine in severe renal impairment. Proactively reduce gabapentinoid doses in renal dysfunction and AKI.
• 5. Optimize Multimodal Analgesia and Monitor Safety: In patients with mixed pain, combine non-opioid modulators with standard analgesics. When combining gabapentinoids and opioids, monitor closely for synergistic respiratory depression and sedation. Incorporate low-dose ketamine infusions (NMDA block) to prevent central sensitisation and counter opioid-induced hyperalgesia .
• 6. Continuous Bedside Reassessment and Escalation: Regularly evaluate pain intensity, functional recovery, and drug-induced side effects. Adjust doses based on daily clinical status and renal clearance. For refractory cases, consult multidisciplinary pain or neurology services early .

REFERENCES

1. Chambers D, Huang C, Matthews G. Basic Physiology for Anaesthetists. 2nd ed. Cambridge: Cambridge University Press; 2019. Chapter 60: Pain Physiology. pp. 272–275. 

2. Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162-173